Symposium presenter banner

Symposium

Of Rising Scholars

2026

Robyn will be presenting at The Symposium of Rising Scholars on Sunday, March 22nd! To attend the event and see Robyn's presentation.

Go to Polygence Scholars page
Robyn Rose's cover illustration
Polygence Scholar2026
Robyn Rose's profile

Robyn Rose

Class of 2027Doylestown, Pennsylvania

About

Projects

  • "Biological Pathways that Link Cancer and Major Depressive Disorders" with mentor Nella (Aug. 7, 2026)

Project Portfolio

Biological Pathways that Link Cancer and Major Depressive Disorders

Started Mar. 12, 2026

Abstract or project description

Cancer is widely recognized as a physical disease, but it can also have significant effects on mental health. Approximately 15–25% of cancer patients experience major depressive disorder (MDD) or clinically significant depressive symptoms, suggesting that depression is more than an emotional response to a cancer diagnosis. Growing evidence indicates that chronic inflammation and immune activation may contribute to cancer-related depression, although the biological mechanisms underlying this relationship are not yet fully understood. This review examines the inflammatory pathway linking cancer and depression, with a particular focus on chronic inflammation, immune activation, inflammatory biomarkers, and their effects on brain function. Current evidence suggests that inflammatory cytokines, including interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and C-reactive protein (CRP), may influence neurotransmitter signaling and contribute to depressive symptoms through multiple biological mechanisms. However, most available evidence remains observational, making it difficult to establish a direct relationship between inflammation and depression. Overall, this review supports the biopsychosocial model by demonstrating that biological, psychological, and social factors likely interact to influence depression in cancer patients. A better understanding of these mechanisms may improve the recognition and management of depression while guiding future research and more personalized approaches to cancer care.